Test ID: 702

Test-Substance: CBD

90-Day Oral Toxicity Study in Rodents CBD:

  • Test: Sub-chronic toxicity study – 90-Day Oral Toxicity Study
  • Guideline: OECD Test Guideline No. 408
  • Testing Facility: Academic study / GLP compliant
  • Date of Testing: 12/2020 - 02/2021
  • Test-Substance: -(-) trans Cannabidiol, synthesized

Summary: In accordance with OECD Test Guideline No. 408 at a GLP-compliant testing facility, the study revealed that no signs of changed survival data, body weight, diet or water consumption, blood count or biochemical parameters, macroscopic or microscopic changes in organs could be detected at concentrations of 0.66 mg/kg bw/day (10 animals). Furthermore, no signs of toxicity could be found.

Categorisation according to Klimisch et al. 1997: "reliable without restriction"

The following price (net) is requested by the study owner: 60 000€ (incl. Test ID 703: Comet Assay/CBD and Test ID 704: BRMT-Test/CBD) (please note: This is the price the study owner is asking for the study)

 

Test ID: 708

Test-Substance: CBG

90-Day Oral Toxicity Study in Rodents CBG:

  • Test: Sub-chronic toxicity study – 90-Day Oral Toxicity Study
  • Guideline: OECD Test Guideline No. 408 (incl. summary of a Comet Assay – OECD No. 489)
  • Testing Facility: Academic study / GLP compliant
  • Date of Testing: 2023
  • Test-Substance: Cannabigerol, isolated

Summary: In accordance with OECD Test Guideline No. 408 (incl. OECD Test Guideline No. 489) at a GLP-compliant testing facility, the study revealed no changes in survival data and no changes in water or diet consumption. However, toxicity was observed through signs of oxidative stress at concentrations of 0.66 mg/kg/day and 1.33 mg/kg bw/day. No single-dose pharmacokinetic study was conducted. No genotoxic potential was detected in blood samples or liver cells.

Categorisation according to Klimisch et al. 1997: "reliable without restriction"

The following price (net) is requested by the study owner: 55 000€